TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Dimerix Limited ( (AU:DXB) ).
Dimerix Limited announced a change in the director’s interest, specifically regarding Sonia Poli. The notice detailed the lapse of 47 listed options due to expiry, resulting in no change in the number of ordinary shares held by the director. This update reflects routine adjustments in the director’s securities holdings, with no immediate impact on the company’s operations or market positioning.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited operates in the biotechnology industry, focusing on the development of innovative pharmaceutical products. The company is involved in creating therapies for unmet medical needs, particularly in the area of chronic kidney disease and other related conditions.
Average Trading Volume: 3,339,241
Technical Sentiment Signal: Buy
Current Market Cap: A$348.1M
For a thorough assessment of DXB stock, go to TipRanks’ Stock Analysis page.